跳至主要内容
临床试验/CTRI/2024/07/070216
CTRI/2024/07/070216尚未招募2 期

Clinical study to evaluate effect of iCare plus in management of health during menopause period. A quality-of-life clinical study

IndusViva Healthsciences Pvt Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年7月29日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
Changes in Menopause Rating scale, hot flushes, night sweats, anxiety, stress, joint pain and other symptoms of menopause

研究概览

简要总结

The main objective of the trial is to evaluate benefit of IP in Reduction in Hot flashes, Reduction in Night sweats, coping up with anxiety & stress, Reduced Muscle & Joint pains, Feel Energetic, help weight management, Overcoming Vaginal Dryness, FSH & Estrogen (estradiol), Luteinizing hormone, through MENQOL and MRS QOL questionnaire to evaluate general health and wellbeing during menopause and to assess the safety of the iCare+.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
40.00 Year(s) 至 50.00 Year(s)(—)
性别
Female

入选标准

  • 1.Women aged over 40 2.Subjects going through menopause 3.Subjects who voluntarily agree to participate in this clinical trial in writing 4.Subjects who have more than 2 symptoms according to menopause care QOL.

排除标准

  • 1.Subjects with hysterectomy or oophorectomy 2.PCOD or similar condition 3.Subjects who are on steroids for certain health conditions 4.Subjects who refuse to sign the informed consent form.

结局指标

主要结局

Changes in Menopause Rating scale, hot flushes, night sweats, anxiety, stress, joint pain and other symptoms of menopause

时间窗: baseline, 3rd month and 6th month.

次要结局

  • changes in lab values for estrogen, FSH and LH. Also, safety of IP(baseline, 3rd month and 6th month.)

研究者

发起方
IndusViva Healthsciences Pvt Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Hema Divakar

Divakars Speciality Hospital

研究点 (1)

Loading locations...

相似试验